• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Idera Pharmaceuticals - Articles and news items

lymphoma

Idera announces FDA orphan drug designation for IMO-8400 for the treatment of diffuse large B-cell lymphoma

Industry news / 2 April 2015 / Victoria White

Idera has announced that the FDA has granted orphan drug designation for IMO-8400 for the treatment of diffuse large B-cell lymphoma (DLBCL)…

Idera Pharmaceuticals Logo

Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100

Industry news, News / 20 July 2011 / Idera Pharmaceuticals

Idera Pharmaceuticals announced the receipt of a verbal communication from the U.S. FDA that a proposed Phase 2 protocol…

Idera Pharmaceuticals logo

Idera Pharmaceuticals delays initiation of Phase 2 clinical trial of IMO-2125 in treatment-naïve HCV patients

Industry news, News / 22 April 2011 / Idera Pharmaceuticals, Inc.

Delay is based on preliminary data from a 26-week nonclinical toxicology study…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +